Pulmonary paracoccidioidomycosis (PCM) relies on a finely balanced lung-immune network in which Th17, Treg, neutrophils, and macrophages orchestrate fungal control and tissue integrity. Furthermore, within the context of single-cell sequencing, little is known about how immune checkpoint inhibition modulates this balance during systemic mycosis. In a previous study we verified that the blockade of checkpoint molecules (CTLA-4 and PD-1) restores protective immunity that reduces fungal loads, tissue pathology and mortality of infected mice. Here, we have further studied this model by single-cell RNA sequencing on lung leukocytes from mice infected with Paracoccidioides brasiliensis and treated with anti-CTLA-4 or anti-PD-1 antibodies to define the cellular and molecular consequences of checkpoint blockade in vivo. We generated a high-resolution atlas covering T cells, neutrophils, macrophages/monocytes, B cells, NK cells, and epithelial subsets. Checkpoint inhibition consistently remodeled the CD4⁺ T cell compartment toward a Th17-enriched program, with reduced interleukin-10 expressing Treg frequencies and a prominent interleukin-17A⁺ (IL-17), C-C chemokine receptor type 2⁺, CXC chemokine (CXC) receptor type 6⁺, CD44⁺ ( Il17a ⁺ Ccr2 ⁺ Cxcr6 ⁺ Cd44 ⁺) signature. This shift was accompanied by the expansion and activation of neutrophils and macrophages expressing tumor necrosis factor and chemokines (including CXC motif chemokine ligand ( Cxcl 1, Cxcl2 and Ccl4 ), microbicidal-associated genes (S100 calcium-binding protein A8 and A9), and regulatory mediators such as secretory leukocyte protease inhibitor and interleukin-15. Ligand–receptor and trajectory analyses revealed a reinforced Th17–myeloid communication axis, particularly under CTLA-4 blockade, converging on IL17–centered inflammatory circuits while attenuating canonical Treg checkpoints (cytotoxic T-lymphocyte-associated protein 4, programmed cell death protein 1, interleukin-10). Together, these data demonstrate that anti-CTLA-4 and anti-PD-1 immunotherapies profoundly rewire the lung-immune microenvironment during PCM, amplifying effector Th17–neutrophil–macrophage networks that benefits protective antifungal activity Our work provides a mechanistic framework for evaluating immune checkpoint inhibitors in chronic fungal infections.